The stock of Akebia Therapeutics Inc. (NASDAQ:AKBA) increased by $0.23 on Monday to finish at $1.38, up 20.00 percent. The last five days have seen an average of 1,826,480 shares of common stock traded. 14 times new highs were reached in the current year, with a gain of $0.8030. The average number of shares traded over the last 20 days was 1,838,615, while the average volume over the last 50 days totaled 1,948,278.
AKBA stock dropped -12.66% since last month. On 08/25/23, the company’s shares reached a one-month low of $1.1200. The stock touched a high of $1.84 on 08/01/23, after rallying from a low of $0.24 in 52 weeks. The price of AKBA stock has risen by 139.17% or $0.8030 this year, reaching a new high 14 times. Still, the stock price is down -25.00% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
AKBA stock investors should be aware that Akebia Therapeutics Inc. (AKBA) stock had its last reported insider trading activity 96 days ago on May 25. On May 25, SVP, Chief Operating Officer Dahan Michel sold 95,478 shares at $1.22 each. This transaction resulted in the insider making $116,760. On May 25, Hadas Nicole R. sold 63,186 shares at a price of US$1.22. After the transaction, the insider now owns 524,344 shares. SVP, Chief Medical Officer Burke Steven Keith had earlier sold 63,567 shares on May 16 for $1.07 a share. The transaction was completed for $67,890.
Financial Health
For the three months ended June 29, Akebia Therapeutics Inc.’s quick ratio was 1.20, while its current ratio was 1.50, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 85.30% percent. Akebia Therapeutics Inc.’s EBITDA margin for the year ended June 29 was -9.54%, whereas its operating margin stood at -29.40% for the same period. Based on annual data, it had gross profit of $207.81 million and revenue of $292.6 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AKBA’s return on assets (ROA) during the last 12 months has been -23.30%. There was a -106.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -519.50%.
Earnings Surprise
According to Akebia Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $40.13 million, while revenues fell by -53.75% to $55.18 million. It was predicted that Akebia Therapeutics Inc.’s quarterly earnings would be -$0.06, but it ended up being -$0.02. EBITDA was -$15.53 million for the quarter. At the end of Akebia Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 291.21 million, while its total debt was $82.87 million. Equity owned by shareholders amounts to $185.93 million.
Technical Picture
Here’s a quick look at Akebia Therapeutics Inc.’s (AKBA) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 55.17%, suggesting the stock is Neutral, with a 110.71% historical volatility rate.
The stochastic %K and %D were 22.94% and 17.38% respectively, while the average true range (ATR) was 0.1431. Based on the 14-day stochastic reading of 50.00%, the RSI (14) reading is 53.16%. On the 9-day MACD Oscillator, the stock is at 0.0022, and the 14-day reading is at -0.0393.
Analyst Ratings
In its most recent analyst report, H.C. Wainwright raised its rating on Akebia Therapeutics Inc. (NASDAQ: AKBA) to a Buy. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Akebia Therapeutics Inc. (AKBA) an Buy rating. AKBA is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 2 others recommend it as a buy.
What is AKBA’s price target for the next 12 months?
The current consensus forecast for the stock is between $3.75 and $4.00, with a median target price of $3.88. In analyzing these forecasts, the average price target given by analysts for Akebia Therapeutics Inc. (AKBA) is $3.88.
